148 related articles for article (PubMed ID: 29112651)
1. Progesterone for Prevention of Preterm Birth: Shortcomings and Unintended Consequences of the Orphan Drug Act.
Gee RE; Kuy S; Karas LO
Obstet Gynecol; 2017 Dec; 130(6):1202-1206. PubMed ID: 29112651
[TBL] [Abstract][Full Text] [Related]
2. 17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population.
Orsulak MK; Block-Abraham D; Gee RE
Clin Ther; 2015 Apr; 37(4):727-32. PubMed ID: 25700945
[TBL] [Abstract][Full Text] [Related]
3. Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate).
Cohen AW; Copel JA; Macones GA; Menard MK; Riley L; Saade GR
Obstet Gynecol; 2011 Jun; 117(6):1408-1412. PubMed ID: 21471853
[TBL] [Abstract][Full Text] [Related]
4. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
[TBL] [Abstract][Full Text] [Related]
5. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Nelson DB; McIntire DD; Leveno KJ
Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
[TBL] [Abstract][Full Text] [Related]
6. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
Yee LM; Liu LY; Sakowicz A; Bolden JR; Miller ES
Am J Obstet Gynecol; 2016 Mar; 214(3):374.e1-6. PubMed ID: 26829989
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
9. Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate.
;
Am J Obstet Gynecol; 2023 Jul; 229(1):B2-B6. PubMed ID: 37061078
[TBL] [Abstract][Full Text] [Related]
10. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
[TBL] [Abstract][Full Text] [Related]
11. Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale.
Godlewski BJ; Sobolik LI; King VJ; Harrod CS
Obstet Gynecol; 2020 May; 135(5):1207-1213. PubMed ID: 32282587
[TBL] [Abstract][Full Text] [Related]
12. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
[TBL] [Abstract][Full Text] [Related]
13. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
[TBL] [Abstract][Full Text] [Related]
14. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO; Stamilio DM; Macones GA; Polsky D
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
[TBL] [Abstract][Full Text] [Related]
15. Utilization of hydroxyprogesterone caproate among pregnancies with live birth deliveries in the sentinel distributed database.
Shinde M; Cosgrove A; Woods CM; Chang C; Nguyen CP; Moeny D; Ajao A; Kolonoski J; Tsai HT
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6291-6296. PubMed ID: 33926341
[TBL] [Abstract][Full Text] [Related]
16. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Manuck TA
Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
[TBL] [Abstract][Full Text] [Related]
17. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Merlob P; Stahl B; Klinger G
Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
[TBL] [Abstract][Full Text] [Related]
18. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
19. Inequality and Innovation: Barriers and Facilitators to 17P Administration to Prevent Preterm Birth among Medicaid Participants.
Cross-Barnet C; Benatar S; Courtot B; Hill I; Johnston E; Cheeks M
Matern Child Health J; 2018 Nov; 22(11):1607-1616. PubMed ID: 29956128
[TBL] [Abstract][Full Text] [Related]
20. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
